These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 19786391)
1. What extent of weight loss can benefit the health-related quality of life in motivated obese Chinese? Wu CH; Kuo HC; Chang CS; Yu C Asia Pac J Clin Nutr; 2009; 18(3):423-32. PubMed ID: 19786391 [TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Kaukua JK; Pekkarinen TA; Rissanen AM Int J Obes Relat Metab Disord; 2004 Apr; 28(4):600-5. PubMed ID: 14770192 [TBL] [Abstract][Full Text] [Related]
3. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. Samsa GP; Kolotkin RL; Williams GR; Nguyen MH; Mendel CM Am J Manag Care; 2001 Sep; 7(9):875-83. PubMed ID: 11570021 [TBL] [Abstract][Full Text] [Related]
4. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. Mathus-Vliegen EM; Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193 [TBL] [Abstract][Full Text] [Related]
5. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Kiortsis DN; Tsouli S; Filippatos TD; Konitsiotis S; Elisaf MS Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):207-10. PubMed ID: 17570651 [TBL] [Abstract][Full Text] [Related]
6. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099 [TBL] [Abstract][Full Text] [Related]
7. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. Hainer V; Kunesova M; Bellisle F; Hill M; Braunerova R; Wagenknecht M Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700 [TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Sari R; Balci MK; Cakir M; Altunbas H; Karayalcin U Endocr Res; 2004 May; 30(2):159-67. PubMed ID: 15473126 [TBL] [Abstract][Full Text] [Related]
9. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. Elfhag K; Finer N; Rössner S Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239 [TBL] [Abstract][Full Text] [Related]
10. The relationship between health-related quality of life and weight loss. Kolotkin RL; Crosby RD; Williams GR; Hartley GG; Nicol S Obes Res; 2001 Sep; 9(9):564-71. PubMed ID: 11557837 [TBL] [Abstract][Full Text] [Related]
11. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343 [TBL] [Abstract][Full Text] [Related]
12. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341 [TBL] [Abstract][Full Text] [Related]
13. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909 [TBL] [Abstract][Full Text] [Related]
14. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients. Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984 [TBL] [Abstract][Full Text] [Related]
15. Combining behavioral and pharmacological treatments for obesity. Phelan S; Wadden TA Obes Res; 2002 Jun; 10(6):560-74. PubMed ID: 12055334 [TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification--a 2-y follow-up study. Kaukua J; Pekkarinen T; Sane T; Mustajoki P Int J Obes Relat Metab Disord; 2003 Oct; 27(10):1233-41. PubMed ID: 14513072 [TBL] [Abstract][Full Text] [Related]
18. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. Gursoy A; Erdogan MF; Cin MO; Cesur M; Baskal N Eat Weight Disord; 2006 Dec; 11(4):e127-32. PubMed ID: 17272944 [TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life following a clinical weight loss intervention among overweight and obese adults: intervention and 24 month follow-up effects. Blissmer B; Riebe D; Dye G; Ruggiero L; Greene G; Caldwell M Health Qual Life Outcomes; 2006 Jul; 4():43. PubMed ID: 16846509 [TBL] [Abstract][Full Text] [Related]
20. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]